• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

guyt@unimelb.edu.au

Credentials


Position
Honorary (Principal Fellow)
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-9873-3592

A/Prof Guy Toner

Honorary (Principal Fellow)
The Sir Peter MacCallum Department of Oncology

186 Scholarly works
3 Projects

HIGHLIGHTS

  • 2026

    Journal article

    The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study
    DOI: 10.1002/bcp.70431
  • 2023

    Journal article

    Patterns of Relapse in Australian Patients with Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations
    DOI: 10.1200/OP.23.00191
  • 2023

    Journal article

    Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
    DOI: 10.1016/j.annonc.2023.09.1116
  • 2022

    Journal article

    Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up
    DOI: 10.1186/s40644-022-00496-w
  • 2022

    Journal article

    High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres
    DOI: 10.1111/bju.15648
  • 2021

    Conference Proceedings

    Exploring the role for FDG-PET/CT in testicular seminoma at diagnosis and during active surveillance across the disease spectrum
  • 2017

    Research Grant

    Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
Guy Toner

RECENT SCHOLARLY WORKS

  • 2021

    Journal article

    Clinical utility of FDG PET-CT in stage 1 and advanced testicular seminoma.
    DOI: 10.1200/JCO.2021.39.15_suppl.5027
  • 2021

    Conference Proceedings

    P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
    DOI: 10.1200/JCO.2021.39.6_suppl.TPS390
  • 2021

    Conference Proceedings

    Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).
    DOI: 10.1200/JCO.2021.39.6_suppl.TPS367
  • 2020

    Conference Proceedings

    P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    DOI: 10.1200/jco.2026.44.7_suppl.tps623

RECENT PROJECTS

  • 2010

    Research Grant

    Novel Methods to Predict the Pharmacology and Effect of Anticancer Drugs
  • 2008

    Research Grant

    Accelerated First Line Chemotherapy for Advanced Germ Cell Tumours

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224